AAP
KYMR icon

Arax Advisory Partners’s Kymera Therapeutics KYMR Stock Holding History

Arax Advisory Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.2K Buy
+176
New +$15.1K ﹤0.01% 3959
2026
Q1 		– Sell
-37
Closed -$2.88K – 4095
2025
Q4 		$2.88K Sell
37
-321
-90% -$21.7K ﹤0.01% 3118
2025
Q3 		$20.3K Buy
+358
New +$16.1K ﹤0.01% 2259

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Arax Advisory Partners's KYMR Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 176 shares worth $20.2K. The stake represents ﹤0.01% of the portfolio and ranks #3959 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in KYMR as recently as Q4 2025.

Arax Advisory Partners first reported a position in KYMR in Q3 2025 and has held it in 3 quarters since. The position peaked at $20.3K in Q3 2025. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Arax Advisory Partners held 176 shares of Kymera Therapeutics worth $20.2K as of Q2 2026.
  • Kymera Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3959 holding.
  • Arax Advisory Partners first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Kymera Therapeutics position peaked at $20.3K in Q3 2025.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.